636 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This pilot trial is crucial as it explores a novel therapeutic avenue for Alcohol Use Disorder (AUD), a condition with significant unmet medical needs. If tirzepatide, a GLP-1/GIP receptor agonist primarily used for d…
The bold challenge of weight regain after successful initial weight loss significantly impacts long-term health outcomes for individuals with obesity. If Retatrutide proves effective in maintaining weight reduction, i…
This trial is crucial because retatrutide, a novel triple agonist targeting GIP, GLP-1, and glucagon receptors, holds significant promise for treating obesity and its complex comorbidities. If successful, it could off…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
The successful modulation of calorie intake and energy expenditure by LY3437943 could represent a significant advancement in obesity treatment. If LY3437943 demonstrates a favorable impact on these parameters, it coul…
If successful, this study could demonstrate a significant cardio-renal protective effect of Retatrutide beyond its known weight-loss benefits. This would be a crucial advancement, as current treatments for obesity oft…
The SYNERGY-OUTCOMES study holds immense significance as it addresses a critical unmet medical need for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition without approved pharmacologic trea…
If successful, this Phase 2 study could demonstrate that LY3437943 is a highly effective and well-tolerated treatment for obesity and overweight with comorbidities, potentially offering a new therapeutic avenue. The e…
A favorable drug-drug interaction profile is a critical factor for the successful development of any new medication, particularly for chronic conditions like obesity where patients often take multiple concomitant drug…
This Phase 3b trial is pivotal for optimizing Retatrutide's clinical utility by identifying the most effective and well-tolerated dosing strategies for long-term use. Understanding the nuances of dose escalation can s…
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
**Inclusion in a formal clinical trials gateway signals that AOD-9604 had reached a stage of development warranting systematic tracking in the peer-reviewed clinical literature.** For clinicians and researchers, this …
This comprehensive review highlighted the diverse and innovative approaches being explored to combat obesity in the early 2000s. The identification of multiple drug classes, from central nervous system modulators to p…
This meta-analysis provides critical evidence that while semaglutide is highly effective for many, a substantial subset of patients experiences suboptimal weight or glycemic improvements or discontinues therapy. This …
This study highlights a significant barrier to effective patient education for widely used medications like semaglutide. Most online semaglutide patient education is inaccessible to the average person, potentially hin…
This research provides novel insights into the neuroprotective mechanisms of Semaglutide, demonstrating its ability to combat obesity-linked neurodegeneration by modulating microglia activation and AD-like pathology t…
This research provides crucial insights into the structural stability and aggregation mechanisms of semaglutide, which is vital for optimizing its formulation and storage. Understanding the pH-dependent formation of β…
The development of these incretin-based medications marks a paradigm shift in obesity treatment, offering pharmacological options with efficacy levels previously only achievable through bariatric surgery. This advance…
This case report highlights a critical safety concern for patients on tirzepatide and SGLT-2 inhibitors, emphasizing the importance of patient education regarding 'sick-day rules.' The finding that these agents can be…
This review highlights a critical gap in our understanding of optimal T2DM management during pregnancy, particularly concerning newer, highly effective antidiabetic agents. The limited evidence for novel therapies mea…